Chimeric antigen receptor T cell

Cancer Gene Therapy Global Market Report 2022: Rapidly Rising Prevalence of Cancer Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 19, 2023
Biotechnology, General Health, Health, Genetics, Oncology, Bacillus, Chimeric antigen receptor T cell, Blood, Overalls, World Health Organization, Ageing, Ferring Pharmaceuticals, Neoplasm, Canadian Cancer Society, Lung cancer, Immunotherapy, Multiple myeloma, Government, DNA, Vector, Death, Immune system, Dove Medical Press, Growth, Food, Therapy, Lymphatic system, Patient, Prevalence, Bone marrow, Research, Cancer, Tata Memorial Centre, Indian Institute of Technology (BHU) Varanasi, US Foods, Breast cancer, Investment, Irish Cancer Society, Pharmaceutical industry, Vaccine

Cancer gene therapy refers to a medical technique for cancer treatment where a therapeutics DNA is introduced in the gene of a cancer patient which eliminates the cancer cell.

Key Points: 
  • Cancer gene therapy refers to a medical technique for cancer treatment where a therapeutics DNA is introduced in the gene of a cancer patient which eliminates the cancer cell.
  • Owing to the rapidly growing prevalence of cancer, the demand for gene therapy products is also projected to increase, thereby boosting the cancer gene therapy market growth during the forecast period.
  • Based on therapy type, the cancer gene therapy market is segmented into immune cell gene therapy, oncolytic virotherapy, gene transfer, and others.
  • Immunotherapy is expected to grow at a relatively higher rate during the forecast period of the cancer gene therapy market.

Sarah Cannon Research Institute to Present Latest Research Insights at the 2022 ASH Annual Meeting & Exposition

Retrieved on: 
Friday, December 9, 2022
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Exposition, Physician, Lymphatic system, Network, Chimeric antigen receptor T cell, Trial of the century, Sarah Cannon Research Institute, Health, Patient, Science, Cancer, Research, McKesson Corporation, GPRC5D, FDA, Drug development, CST, SCRI, Acute leukemia, The Network, Clinical trial, Relapse, Education, Cristian Berdeja, Blood, Pharmaceutical industry, Medicine, MD

Investigators highlighting research at this years ASH Annual Meeting & Exposition represent studies being conducted across SCRI, Sarah Cannon Transplant & Cellular Therapy Network, US Oncology Research, as well as partners from McKessons The US Oncology Network and Ontada.

Key Points: 
  • Investigators highlighting research at this years ASH Annual Meeting & Exposition represent studies being conducted across SCRI, Sarah Cannon Transplant & Cellular Therapy Network, US Oncology Research, as well as partners from McKessons The US Oncology Network and Ontada.
  • Sarah Cannon Research Institute (SCRI) is one of the worlds leading oncology research organizations conducting community-based clinical trials.
  • In 2022, SCRI formed a joint venture with US Oncology Research to enhance clinical trial access and availability across the country.
  • Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development.

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

Retrieved on: 
Friday, November 11, 2022
Gamma, Chimeric antigen receptor T cell, U.S. Securities and Exchange Commission, FDA, SITC, NASDAQ, Adult, Weill Cornell Medicine, Risk, Maintenance, CP, Private Securities Litigation Reform Act, AM, ADCC, NCR Corporation, Neoplasm, Company, Memorial Sloan Kettering Cancer Center, Immunotherapy, CAR, Annual general meeting, Safety, Glossary, IPSC, Poster, Genetic engineering, COVID-19, Event, IND, Intellectual property, Society for Immunotherapy of Cancer, Therapy, Security (finance), CD16, GLOBE, Trastuzumab, B cell, Gene editing, Marketing, T, R, Society, Cancer, Century, Investigational New Drug, MSKCC, Memorial Hospital, Canadian Aviation Regulations, Ink, Research and development, Pharmaceutical industry, Vaccine, Medicine

PHILADELPHIA, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced preclinical data from the Company’s iPSC-based cell therapy platform were featured in two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting. Additionally, the Company provided pipeline program updates ahead of its virtual Research and Development (R&D) Day taking place today, November 11, at 8:00 AM ET.

Key Points: 
  • Additionally, the Company provided pipeline program updates ahead of its virtual Research and Development (R&D) Day taking place today, November 11, at 8:00 AM ET.
  • We look forward to discussing these updates later this morning during our virtual R&D Day.
  • A copy of each poster presentation from the SITC Annual Meeting is available on Centurys website.
  • Preclinical data presented today demonstrate that iPSC-derived T cells derived from reprogrammed primary T cells can be efficiently engineered and produced with robust yield.

Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 10, 2022
GLOBE, CELU, ATM, IND, Acute leukemia, Abstract, U.S. Securities and Exchange Commission, Food, Risk, Communication, EST, Research, Biology, Annual report, GBM, Private Securities Litigation Reform Act, Technology, Sale, HER2, Executive Committee, YA, COVID-19, Securities Act of 1933, Regulation of tobacco by the U.S. Food and Drug Administration, CAR, SEC, Chimeric antigen receptor T cell, Securities Exchange Act of 1934, SITC, Senior, Cancer, Form 10-K, General manager, AML, Clinical trial, Terminology, NK, Patient, Treatment, MRD, Security (finance), Drug Quality and Security Act, Lymphoid leukemia, Degenerative disease, Insurance, Industry, FDA, Income, Pharmaceutical industry, Vaccine, Music, Reinsurance, Instituto de Biologia Molecular e Celular

FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced financial results for the quarter ended September30, 2022, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, today announced financial results for the quarter ended September30, 2022, and provided a corporate update.
  • Celularity submitted an investigational new drug application (IND) for CYCART-19 in the first quarter of 2022, and in May 2022, the FDA requested additional information before Celularity can proceed with the planned first-in-human Phase 1/2 clinical trial of CYCART-19.
  • In September 2022, Celularity received cash proceeds net of discount of approximately $39.2 million as a pre-paid advance from Yorkville.
  • If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.

Grant Awarded to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer

Retrieved on: 
Wednesday, November 9, 2022
B cell, Monocyte, Foundation, Macrophage, FDA, Travel, Lymphatic system, University, MD, Patient, Courage, Infection, Cancer, Immunotherapy, De Gregorio, CAR, Bone marrow, TME, GEMINI, Inflammation, Doctor of Philosophy, Stomach cancer, Genetic engineering, Cell, Chimeric antigen receptor T cell, Multimedia, Vaccine, Pharmaceutical industry

"We reasoned that genetically engineered macrophages may be better suited to treat solid tumors since these cells are the major immune componentinthetumormicroenvironment(TME)."

Key Points: 
  • "We reasoned that genetically engineered macrophages may be better suited to treat solid tumors since these cells are the major immune componentinthetumormicroenvironment(TME)."
  • Macrophages are normally produced from the bone marrow as monocytes, which travel around the bloodstream and lodge at sites of infection, inflammation and cancer.
  • "This grant will allow me to develop a high-risk yet potentially high-reward cancer treatment paradigm," said Dr. Gill.
  • "We are proud to support the development of a new therapeutic platform for gastroesophageal cancer by Dr. Gill," concluded Lynn DeGregorio, President and Founder.

Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Retrieved on: 
Monday, October 17, 2022
Research, Hospitals, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Effectiveness, Population, Royal commission, SOC, HDT, Patient, Standard of care, Research, CAR, Axicabtagene ciloleucel, B-cell lymphoma, Oncology, Cancer research, Institute of Cancer Research, DLBCL, CEO, EFS, Adult, Non-Hodgkin lymphoma, Chimeric antigen receptor T cell, EC, ASCT, European Commission, Pharmaceutical industry

Yescarta is now the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment.

Key Points: 
  • Yescarta is now the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment.
  • Diffuse large B-cell lymphoma (DLBCL) is the most common sub-type of non-Hodgkin lymphoma (NHL), representing around 30% of cases.
  • Yescarta was first approved in Europe in 2018 and is currently indicated for five types of blood cancer: Diffuse Large B-Cell Lymphoma (DLBCL); Large B-Cell Lymphoma (LBCL); High-Grade B-Cell Lymphoma (HGBL); Primary Mediastinal Large B-Cell Lymphoma (PMBCL); and Follicular Lymphoma (FL).
  • Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product

Retrieved on: 
Monday, October 3, 2022
Oncology, Health, FDA, Hospitals, Genetics, Pharmaceutical, Biotechnology, YouTube, Cancer, Hospital, U.S. Securities and Exchange Commission, Gilead Sciences, Physician, LinkedIn, Clinical trial, Chimeric antigen receptor T cell, Private Securities Litigation Reform Act, Food, Lymphatic system, Blood, FDA, Medicine, HIV, Cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, RVV, Risk, Social media, CAR, Securities and Exchange Commission (Philippines), Vaccine, Pharmaceutical industry, Facebook, Twitter

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.

Key Points: 
  • Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.
  • Kite is the only cell therapy company with in-house commercial and clinical trial viral vector manufacturing capabilities, augmenting its strong external supply partners.
  • This forms the largest dedicated in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial production and commercial product manufacturing.
  • The capabilities and operations are fully scalable and will allow Kite to accommodate additional vector manufacturing as cell therapy science advances.

CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy

Retrieved on: 
Monday, September 26, 2022
Chimeric antigen receptor T cell, IPSC, Hangzhou, Zhejiang University, CGMP, Principal, Macrophage, Partnership, NK, Patient, Harvard University, Cancer, Seattle, Drug development, Research, Marketing, Noval, Fine chemical

HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- CellOrigin Biotech (Hangzhou) Co., Ltd. announced it has made a global strategic collaboration agreement with Qilu Pharma to develop, manufacture and commercialize proprietary "off-the-shelf" induced pluripotent stem cell- (iPSC) derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immunotherapy.

Key Points: 
  • HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- CellOrigin Biotech (Hangzhou) Co., Ltd. announced it has made a global strategic collaboration agreement with Qilu Pharma to develop, manufacture and commercialize proprietary "off-the-shelf" induced pluripotent stem cell- (iPSC) derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immunotherapy.
  • "Innovation and offering the best products that benefit patients are the core values that CellOrigin Biotech and Qilu Pharma both appreciate," said Dr. Jin Zhang, the Co-Founder of CellOrigin Biotech and a Principal Investigator of Zhejiang University, one of the top universities in China.
  • "Meanwhile, we will continue to seek other potential collaborators to jointly develop our innovative anti-tumor CAR-iMac cell products."
  • It is an ideal strategic partner for novel cell therapy, and it is our pleasure to collaborate with such a great biotech company," said Qilu Pharma.

Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001

Retrieved on: 
Thursday, September 22, 2022
Other Manufacturing, Research, Clinical Trials, Stem Cells, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Oncology, Institute, Regenerative medicine, Chimeric antigen receptor T cell, Time, Quality control, ATMP, Advanced Therapy Medicinal Product, CGMP, ADI, Stem cell, CAR, Partnership, Immunotherapy, NK, Patient, Ministry of Education (Malaysia), FUI, Technology, SAS, Cell, CDMO, Lymphatic system, Contract, Microsoft, Multimedia, Lymphoma, GMP, Astellas Institute for Regenerative Medicine, University Hospital Center Dr Dragiša Mišović, Vaccine, Fine chemical, Pharmaceutical industry, Exosome

Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercells lead product.

Key Points: 
  • Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercells lead product.
  • Its patented manufacturing process allows a complete industrialization by using the same batch of NK cells for multiple patients.
  • Cell-Easy is an analytics-driven Contract Development and Manufacturing Organization (CDMO) specialized in the production of Gene-modified Cell and Cell Therapy products.
  • Emercell has signed a strategic agreement with Cell-Easy specialized in the development and production of ATMP.

Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Retrieved on: 
Friday, September 16, 2022
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Adult, Chimeric antigen receptor T cell, Committee for Medicinal Products for Human Use, Hematology, European Medicines Agency, Axicabtagene ciloleucel, European Commission, Patient, B-cell lymphoma, SOC, CEO, Quality of life, Standard of care, CHMP, EFS, Committee, Marketing, EMA, CAR, DLBCL, Pharmaceutical industry

If approved, Yescarta will be the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment.

Key Points: 
  • If approved, Yescarta will be the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment.
  • The European Commission will review the CHMP opinion, and a final decision on the marketing authorization is expected in the coming months.
  • Yescarta was first approved in Europe in 2018 and is currently indicated for three types of blood cancer: Diffuse Large B-Cell Lymphoma (DLBCL); Primary Mediastinal Large B-Cell Lymphoma (PMBCL); and Follicular Lymphoma (FL).
  • Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.